549 related articles for article (PubMed ID: 24707185)
1. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
Levitan B; Yuan Z; Turpie AG; Friedman RJ; Homering M; Berlin JA; Berkowitz SD; Weinstein RB; DiBattiste PM
Vasc Health Risk Manag; 2014; 10():157-67. PubMed ID: 24707185
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Cao YB; Zhang JD; Shen H; Jiang YY
Eur J Clin Pharmacol; 2010 Nov; 66(11):1099-108. PubMed ID: 20812009
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Trkulja V; Kolundzic R
Croat Med J; 2010 Apr; 51(2):113-23. PubMed ID: 20401953
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.
Kwong LM
Vasc Health Risk Manag; 2011; 7():461-6. PubMed ID: 21822393
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Kwong LM
Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
Ning GZ; Kan SL; Chen LX; Shangguan L; Feng SQ; Zhou Y
Sci Rep; 2016 Mar; 6():23726. PubMed ID: 27020475
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis.
Liu J; Zhao J; Yan Y; Su J
Medicine (Baltimore); 2019 Mar; 98(9):e14539. PubMed ID: 30817570
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
14. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
Sindali K; Rose B; Soueid H; Jeer P; Saran D; Shrivastava R
Eur J Orthop Surg Traumatol; 2013 May; 23(4):481-6. PubMed ID: 23412293
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty.
Piple AS; Wang JC; Kang HP; Mills ES; Mayfield CK; Lieberman JR; Christ AB; Heckmann ND
J Arthroplasty; 2023 Aug; 38(8):1613-1620.e4. PubMed ID: 36805121
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Gómez-Outes A; Terleira-Fernández AI; Suárez-Gea ML; Vargas-Castrillón E
BMJ; 2012 Jun; 344():e3675. PubMed ID: 22700784
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Fisher WD; Eriksson BI; Bauer KA; Borris L; Dahl OE; Gent M; Haas S; Homering M; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
[TBL] [Abstract][Full Text] [Related]
19. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
Ricket AL; Stewart DW; Wood RC; Cornett L; Odle B; Cluck D; Freshour J; El-Bazouni H
Ann Pharmacother; 2016 Apr; 50(4):270-5. PubMed ID: 26783354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
